NO20033165D0 - (+)-1-(3,4-diklorfenyl)-3-azabicyklo[3.1.0]heksan, sammensetning og anvendelse derav - Google Patents

(+)-1-(3,4-diklorfenyl)-3-azabicyklo[3.1.0]heksan, sammensetning og anvendelse derav

Info

Publication number
NO20033165D0
NO20033165D0 NO20033165A NO20033165A NO20033165D0 NO 20033165 D0 NO20033165 D0 NO 20033165D0 NO 20033165 A NO20033165 A NO 20033165A NO 20033165 A NO20033165 A NO 20033165A NO 20033165 D0 NO20033165 D0 NO 20033165D0
Authority
NO
Norway
Prior art keywords
azabicyclo
dichlorophenyl
hexane
composition
Prior art date
Application number
NO20033165A
Other languages
English (en)
Other versions
NO325709B1 (no
NO20033165L (no
Inventor
Arnold Stan Lippa
Joseph William Epstein
Original Assignee
Dov Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dov Pharmaceutical Inc filed Critical Dov Pharmaceutical Inc
Publication of NO20033165D0 publication Critical patent/NO20033165D0/no
Publication of NO20033165L publication Critical patent/NO20033165L/no
Publication of NO325709B1 publication Critical patent/NO325709B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20033165A 2001-01-11 2003-07-10 Anvendelse av (+)-1-(3,4-diklorfenyl)-3-azabicyklo[3.1.0]heksan for fremstilling av medikamenter NO325709B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/758,883 US6372919B1 (en) 2001-01-11 2001-01-11 (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
PCT/US2002/000845 WO2002066427A2 (en) 2001-01-11 2002-01-11 (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof

Publications (3)

Publication Number Publication Date
NO20033165D0 true NO20033165D0 (no) 2003-07-10
NO20033165L NO20033165L (no) 2003-09-04
NO325709B1 NO325709B1 (no) 2008-07-07

Family

ID=25053471

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033165A NO325709B1 (no) 2001-01-11 2003-07-10 Anvendelse av (+)-1-(3,4-diklorfenyl)-3-azabicyklo[3.1.0]heksan for fremstilling av medikamenter

Country Status (19)

Country Link
US (2) US6372919B1 (no)
EP (1) EP1349835B1 (no)
JP (4) JP2005500983A (no)
KR (1) KR20030081384A (no)
CN (2) CN1496349A (no)
AU (1) AU2002251758B2 (no)
BR (1) BR0206434A (no)
CA (1) CA2434616C (no)
CZ (1) CZ306143B6 (no)
HU (1) HUP0302613A3 (no)
IL (2) IL156889A0 (no)
MX (1) MXPA03006210A (no)
NO (1) NO325709B1 (no)
NZ (1) NZ527101A (no)
PL (1) PL364837A1 (no)
RU (1) RU2294926C2 (no)
SK (1) SK10122003A3 (no)
WO (1) WO2002066427A2 (no)
ZA (1) ZA200305440B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20070225351A1 (en) * 2002-01-11 2007-09-27 Lippa Arnold S Methods and compositions for controlling body weight and appetite
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
CZ2006427A3 (cs) * 2003-12-29 2006-11-15 Sepracor Inc. Pyrrolové a pyrazolové inhibitory DAAO
WO2006012476A2 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
CA2574310A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
WO2006012477A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
KR20130004370A (ko) * 2004-08-18 2013-01-09 도브 파마슈티칼 인코포레이티드 아자비사이클로헥산의 신규한 다형체
AU2012203400B2 (en) * 2004-08-18 2015-01-15 Euthymics Bioscience, Inc. Novel polymorphs of azabicyclohexane
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
EP1853234A2 (en) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
CA2957667A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
EP1904059A2 (en) * 2005-07-21 2008-04-02 Wyeth a Corporation of the State of Delaware Method for treating nervous system disorders and conditions
CA2659215C (en) 2005-07-27 2018-07-10 Dov Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
AU2006335174B2 (en) * 2006-01-06 2012-09-06 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
AU2007205114B2 (en) 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
AU2007233041B2 (en) 2006-03-31 2013-05-02 Sepracor Inc. Preparation of chiral amides and amines
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
AU2007296301A1 (en) * 2006-09-11 2008-03-20 Glaxo Group Limited Azabicyclic compounds as inhibitors of monoamines reuptake
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20080234354A1 (en) * 2006-11-21 2008-09-25 Lippa Arnold S Methods And Compositions For Controlling Body Weight And Appetite
KR20090111322A (ko) * 2007-01-18 2009-10-26 세프라코 아이엔시. 디 아미노산 옥시다제의 억제제
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
EP3296289A3 (en) 2007-05-31 2018-06-20 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US8389559B2 (en) 2009-02-09 2013-03-05 Sunovion Pharmaceuticals Inc. Pyrrolidine triple reuptake inhibitors
RU2012102094A (ru) 2009-06-26 2013-08-10 Панацеа Биотек Лтд. Новые азабициклогексаны
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
EP2621902B1 (en) 2010-09-28 2017-04-12 Panacea Biotec Ltd 3-azabicyclo[3.1.0]hexane compounds useful for the treatment of cns disorders
CN102417475A (zh) * 2010-09-28 2012-04-18 江苏恒瑞医药股份有限公司 氮杂双环辛烷类衍生物、其制备方法及其在医药上的应用
CA2834713A1 (en) * 2010-12-03 2012-06-07 Anthony Alexander Mckinney Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
US20140228421A1 (en) * 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20130123238A1 (en) * 2011-11-16 2013-05-16 Anthony Alexander McKINNEY Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders
WO2014182279A1 (en) * 2013-05-07 2014-11-13 Euthymics Bioscience, Inc. Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive and alcohol-related disorders
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
AU2022340539A1 (en) 2021-08-31 2024-03-14 Ethismos Research, Inc. Methods of preventing and treating pain and associated symptoms

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892772A (en) 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
JPS535994B2 (no) 1974-09-26 1978-03-03
US4231935A (en) 1975-07-31 1980-11-04 American Cyanamid Company 1-Phenyl-3-azabicyclo[3.1.0]hexanes
US4088652A (en) 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
US4131611A (en) 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4196120A (en) 1975-07-31 1980-04-01 American Cyanamid Company Azabicyclohexanes, method of use and preparation of the same
US4118393A (en) 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
GR72713B (no) 1976-09-15 1983-12-01 American Cyanamid Co
US4118417A (en) 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
IL65843A (en) 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
CH644580A5 (de) * 1980-01-29 1984-08-15 Hoffmann La Roche Cyclohexen-derivate.
US4435419A (en) 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
DE3324263A1 (de) * 1983-07-06 1985-01-17 Hoechst Ag, 6230 Frankfurt Derivate der 2-azabicyclo(3.1.0)hexan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-azabicyclo(3.1.0)hexan-derivate als zwischenprodukte und verfahren zu deren herstellung
FI910897A (fi) * 1990-02-28 1991-08-29 Lilly Co Eli Foerbaettringar roerande (s)-norfluoxetin.
US5130430A (en) 1990-10-31 1992-07-14 Neurogen Corporation 2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands
US6204284B1 (en) 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
AU702594B2 (en) * 1995-10-13 1999-02-25 Duphar International Research B.V. Process for the preparation of enantiomerically pure imidazolyl compounds
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US20030013740A1 (en) * 1998-03-27 2003-01-16 Martin P. Redmon Stable dosage forms of fluoxetine and its enantiomers
JP4194715B2 (ja) * 1998-08-31 2008-12-10 大正製薬株式会社 ６−フルオロビシクロ［３．１．０］ヘキサン誘導体
JP2000159761A (ja) * 1998-11-30 2000-06-13 Yoshio Takeuchi フルオロサリドマイド
JP4290265B2 (ja) * 1999-03-02 2009-07-01 第一ファインケミカル株式会社 新規な不斉配位子
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent

Also Published As

Publication number Publication date
RU2003124649A (ru) 2005-02-27
IL156889A0 (en) 2004-02-08
AU2002251758B2 (en) 2008-01-03
US7098229B2 (en) 2006-08-29
IL156889A (en) 2010-12-30
CZ20032153A3 (cs) 2003-12-17
JP2015227360A (ja) 2015-12-17
CN101461804A (zh) 2009-06-24
JP2005500983A (ja) 2005-01-13
CA2434616A1 (en) 2002-08-29
KR20030081384A (ko) 2003-10-17
US20040132797A1 (en) 2004-07-08
CN101461804B (zh) 2011-04-13
WO2002066427A2 (en) 2002-08-29
CZ306143B6 (cs) 2016-08-24
CA2434616C (en) 2011-03-29
US6372919B1 (en) 2002-04-16
JP2014028847A (ja) 2014-02-13
CN1496349A (zh) 2004-05-12
NO325709B1 (no) 2008-07-07
NZ527101A (en) 2005-08-26
PL364837A1 (en) 2004-12-27
EP1349835A2 (en) 2003-10-08
ZA200305440B (en) 2004-07-15
SK10122003A3 (sk) 2003-12-02
NO20033165L (no) 2003-09-04
BR0206434A (pt) 2003-12-30
RU2294926C2 (ru) 2007-03-10
HUP0302613A2 (hu) 2003-11-28
EP1349835B1 (en) 2016-03-30
JP2009280605A (ja) 2009-12-03
WO2002066427A3 (en) 2003-03-13
HUP0302613A3 (en) 2007-09-28
MXPA03006210A (es) 2004-10-15

Similar Documents

Publication Publication Date Title
NO20033165L (no) (+)-1-(3,4-diklorfenyl)-3-azabicyklo[3.1.0]heksan, sammensetning og anvendelse derav
DE60220778D1 (en) 3,4-disubstituierte cyclobuten-1,2-dione als cxc-chemokinrezeptorliganden
NO20055568D0 (no) Substituerte 1,4-diazepiner og anvendelser derav
IL166216A0 (en) 3,10, and 12a substituted tetracycline compounds
HUP0303825A3 (en) 1h-benzimidazole and 3h-imidazo-[4,5b]pyridine-derivatives, their use and pharmaceutical compositions containing them
SI1555267T1 (sl) 2,3-DIHIDRO-6-NITROIMIDAZO(2,1-b)OKSAZOLI
IL176283A0 (en) Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
HUP0402566A3 (en) C-5 modified indazolylamino pyrrolotriazines, their use and pharmaceutical compositions containing them
EP1575534A4 (en) D4.5 GLYCURONIDASE AND ITS USES
AU2002360733A8 (en) Substituted 4,9-dihydrocyclopenta(imn)phenanthridine-5-ones derivatives thereof and their uses
HUP0500871A3 (en) 5-aryltetrazole compounds, compositions thereof and their use
IS7060A (is) 2,5-díarýlpýrasín, 2,5-díarýlpýridín og 2,5-díarýlpýrimidín sem CRF1 viðtakabeinar
ZA200206808B (en) Endoparasiticidal gel composition.
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
MXPA03006629A (es) Composicion para el cuidado de la piel.
MXPA03007314A (es) Composicion para la piel para reducir aceites y grasa de la piel.
ZA200306923B (en) Fungicide compositions.
IL164887A0 (en) Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
MXPA03001783A (es) N-(3,5-dicloro-2-metoxifenil)-4-metoxi-3- piperazin-1 -il -bencenosulfonamida.
IL162310A0 (en) 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives
AP2003002914A0 (en) Novel expression vectors and uses thereof.
HK1066022A1 (en) Use of 1,1,1,3,3-pentafluorobutan
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
AU7865000A (en) Fused 1-(2,6-dichloro-4-trifluoromethylphenyl)-pyrazoles, the synthesis thereof and the use thereof as pesticides
IL162223A0 (en) 1,3-Diarylprop-2-en-1-ones, compositions containing same and use thereof

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees